We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+47.1%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$707M
AUM Growth
+$213M
Cap. Flow
+$16.4M
Cap. Flow %
2.32%
Top 10 Hldgs %
72.97%
Holding
51
New
11
Increased
9
Reduced
11
Closed
8

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$13.9M
2
ALKS icon
Alkermes
ALKS
+$12.7M
3
ANNX icon
Annexon
ANNX
+$6.46M
4
DERM icon
Journey Medical
DERM
+$6.35M
5
TMCI icon
Treace Medical Concepts
TMCI
+$4.59M

Top Sells

Rank Stock Value
1
VIGL
Vigil Neuroscience
VIGL
+$7.95M
2
ANIK icon
Anika Therapeutics
ANIK
+$6.23M
3
DNA icon
Ginkgo Bioworks
DNA
+$5.63M
4
ARVN icon
Arvinas
ARVN
+$5.25M
5
EPIX
ESSA Pharma
EPIX
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 99.35%
2 Miscellaneous 0.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HROW icon
1
Harrow
HROW
$1.4B
$188M 26.6%
3,905,000
– –
ETON icon
2
Eton Pharmaceutcials
ETON
$1.71B
$62.1M 8.79%
2,860,000
– –
LQDA icon
3
Liquidia Corp
LQDA
$6.06B
$59.5M 8.41%
2,615,000
+140,000
+6% +$3.04M
RYTM icon
4
Rhythm Pharmaceuticals
RYTM
$7.38B
$46.6M 6.59%
461,700
-13,300
-3% -$1.23M
IMNM icon
5
Immunome
IMNM
$3.13B
$37.3M 5.27%
3,185,000
-344,581
-10% -$3.43M
SNWV
6
SANUWAVE Health Inc
SNWV
$40.2M
$36.7M 5.19%
980,000
– –
CDXS icon
7
Codexis
CDXS
$174M
$31.2M 4.41%
12,795,000
+195,000
+2% +$532K
TGTX icon
8
TG Therapeutics
TGTX
$8.26B
$19.3M 2.73%
535,000
– –
OCUL icon
9
Ocular Therapeutix
OCUL
$2.28B
$18.6M 2.64%
1,595,000
– –
CGON icon
10
CG Oncology
CGON
$6.59B
$16.5M 2.33%
410,000
+144,000
+54% +$4.19M
STOK icon
11
Stoke Therapeutics
STOK
$2.04B
$16M 2.27%
682,017
+119,897
+21% +$2.05M
APGE icon
12
Apogee Therapeutics
APGE
$10.2B
$14.4M 2.04%
+363,257
New +$13.9M
ALKS icon
13
Alkermes
ALKS
$7.95B
$13.5M 1.91%
+450,000
New +$12.7M
IRON icon
14
Disc Medicine
IRON
$3.07B
$12.8M 1.81%
193,773
+7,355
+4% +$438K
SRPT icon
15
Sarepta Therapeutics
SRPT
$2.2B
$11.3M 1.59%
585,000
+85,000
+17% +$1.52M
LRMR icon
16
Larimar Therapeutics
LRMR
$417M
$10.6M 1.49%
3,720,867
-389,133
-9% -$1.46M
XOMA
17
DELISTED
Xoma
XOMA
$9.83M 1.39%
255,087
– –
RZLT icon
18
Rezolute
RZLT
$445M
$8.49M 1.2%
903,442
– –
ARVN icon
19
Arvinas
ARVN
$600M
$8.42M 1.19%
987,818
-692,182
-41% -$5.25M
EWTX icon
20
Edgewise Therapeutics
EWTX
$4.64B
$8.11M 1.15%
500,000
+10,000
+2% +$142K
ANNX icon
21
Annexon
ANNX
$942M
$7.93M 1.12%
+2,600,000
New +$6.46M
GOSS icon
22
Gossamer Bio
GOSS
$83.2M
$7.17M 1.01%
2,725,000
-820,000
-23% -$1.81M
PTGX icon
23
Protagonist Therapeutics
PTGX
$9.34B
$6.98M 0.99%
105,000
– –
DERM icon
24
Journey Medical
DERM
$211M
$6.91M 0.98%
971,064
+876,064
+922% +$6.35M
SLGL icon
25
Sol-Gel Technologies
SLGL
$225M
$5.97M 0.84%
+204,835
New +$3.66M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2025 Portfolio in Review

As of Q3 2025, Opaleye Management held 51 positions worth $707M, up 43% from $494M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Opaleye Management's Q3 2025 filing shows 11 new, 9 increased, 11 reduced and 8 closed positions. Its largest new stake was Apogee Therapeutics: 363,257 shares worth $14.4M. The largest sale was Vigil Neuroscience, an estimated $7.95M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q3 2025 buy was Apogee Therapeutics: 363,257 shares worth $14.4M.
  • Opaleye Management added most to Journey Medical in Q3 2025, an estimated $6.35M increase.
  • Opaleye Management's biggest Q3 2025 reduction was Arvinas, cutting an estimated $5.25M.
  • Opaleye Management fully exited Vigil Neuroscience in Q3 2025, selling an estimated $7.95M.
  • Opaleye Management's ten largest holdings make up 73% of its $707M portfolio in Q3 2025.
  • Opaleye Management opened 11 new positions and closed 8 in Q3 2025.
  • Opaleye Management's portfolio value rose 43% quarter-over-quarter to $707M.

Based on Opaleye Management's 13F filing for Q3 2025, filed 14 Nov 2025.